CBD has lower affinity for CB receptors. It functions being an antagonist or partial antagonist at endogenous cannabinoid receptors (each CB1 and CB2 receptor sorts and other G-protein-coupled receptors [GPCRs]) by inhibiting comprehensive binding of direct ligands, and will act generally at all